← ANALYST RATINGS · TIPRANKS
MannKind (MNKD): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy1 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $4.88, the highest $5.00, the lowest $4.75. The average is +60.4% from the last price of $3.04.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 18.10.26on TipRanks Oct 17 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $3.50+16.7% | Hold | +15.1% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −1.3% | Upgrade | 11.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $6.00 → $5.00−16.7% | Buy | +64.5% | Reiterated | 08.10.26on TipRanks 22:25 | −4.4%next day −4.8% · 5 days −5.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +15.1% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +15.1% | Upgrade | 08.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +15.1% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +15.1% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +15.1% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +15.1% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $4.00+14.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $4.00+33.3% | Hold | +31.6% | Upgrade | 01.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $4.00+14.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $4.00+14.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $4.00+14.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $4.00+14.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 08:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 | Hold | +15.1% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 | Sell | −1.3% | Downgrade | 30.09.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | +15.1% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | +15.1% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 | Hold | +15.1% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +15.1% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $6.00 | Buy | +97.4% | Reiterated | 30.09.26on TipRanks 13:15 | +17.0%next day +1.1% · 5 days −13.5% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $10.00 | Buy | +228.9% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | −2.7%next day −0.3% · 5 days −3.3% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $8.00 | Buy | +163.2% | Reiterated | 10.09.26on TipRanks Sep 11 07:55 | −3.2%next day −1.9% · 5 days −6.2% | ↗ |
| Unknown Analyst | Leerink Partners | $4.16 | Buy | +36.8% | Reiterated | 10.09.26on TipRanks 09:15 | −3.2%next day −1.9% · 5 days −6.2% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $13.00 | Buy | +327.6% | Reiterated | 02.09.26on TipRanks 11:00 | +1.1%next day −3.0% · 5 days −5.2% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $8.00 | Buy | +163.2% | Reiterated | 06.08.26on TipRanks 07:30 | −5.0%next day +5.0% · 5 days −5.3% | ↗ |
| Douglas Miehm★★★★★★★★★★#2559 · hits 51% · avg +5.3% | RBC Capital | $4.75 | Hold | +56.2% | Reiterated | 06.08.26on TipRanks 07:25 | −5.0%next day +5.0% · 5 days −5.3% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $8.00 → $7.00−12.5% | Buy | +130.3% | Reiterated | 07.05.26on TipRanks 07:25 | 0.0%next day −1.7% · 5 days −11.6% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $8.00 → $7.00−12.5% | Buy | +130.3% | Reiterated | 27.02.26on TipRanks 08:00 | +1.7%next day −7.5% · 5 days −18.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering MannKind
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.70 at a price of $3.90 (+97.5%); now: $7.56 at $3.04 (+148.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 2 | 3 | 2 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.10 to $-0.03). Last quarter: $-0.06.
Sales
Next quarter’s sales estimate — $109M (from $103M to $118M). Last quarter: $109M.
Best top-analyst consensus in the sector · Healthcare
About MannKind
- CEO: Michael E. Castagna
- Employees: 592
- 1 Casper Street, Danbury, CA, 06810, US
- www.mannkindcorp.com
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Data from the stock’s TipRanks forecast page, read 20 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗